Landiolol : List of nationally authorised medicinal products - PSUSA/00010570/202302
Human medicines European public assessment report (EPAR): Tasigna, nilotinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 19/11/2007, Revision: 45, Status: Authorised
Human medicines European public assessment report (EPAR): Somavert, pegvisomant, Acromegaly, Date of authorisation: 12/11/2002, Revision: 28, Status: Authorised
Second bilateral meeting between European Medicines Agency (EMA) and Vaccines Europe, European Medicines Agency, Amsterdam, the Netherlands, from 27/11/2023 to 27/11/2023
Somavert : EPAR - Procedural steps taken before authorisation
Human medicines European public assessment report (EPAR): Holoclar, ex vivo expanded autologous human corneal epithelial cells containing stem cells, Stem Cell Transplantation;Corneal Diseases, Date of authorisation: 17/02/2015, Revision: 10, Status: Authorised
EVVet3 EVWeb Production – Release notes
EVVET - EVWEB user manual
Human medicines European public assessment report (EPAR): Betaferon, interferon beta-1b, Multiple Sclerosis, Date of authorisation: 30/11/1995, Revision: 36, Status: Authorised
We are pleased to announce that the following EFIM General Assembly will take place on Wednesday, 6 March 2024 at the Istanbul Congress Center in Turkey.
The meeting will take place prior to the 22nd European Congress of Internal Medicine, ECIM, 2024
To be able to register to the General Assembly, please follow the registration link:
https://efim.org/efim-general-assembly-2024-6-march-istanbul